The purpose of SMA Europe is to provide a framework to stimulate collaboration and accelerate translational research pathways in SMA and promote patient care.

  1. Potential SMA Treatment granted orphan medicinal product designation by the European Medicines Agency (EMA)

    Cytokinetics announced that the European Medicines Agency (EMA) has granted orphan medicinal product designation to reldesemtiv for the potential treatment of SMA. Reldesemtiv is a drug that has been shown, in the laboratory, to increase the force generated by skeletal muscle and which delays the onset and extent of muscle fatigue. This could be beneficial to people living with SMA […]


  2. Potential biomarker for SMA identified

    Biogen presented data at the American Academy of Neurology 2019 conference on a potential biomarker for SMA. Biomarkers provide insight on disease progression.  Researchers have found that raised plasma levels of a protein called pNF-H indicate neurological damage and have potential to predict disease activity. The advantage of pNF-H is that it is present in […]